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Abstract Huntington disease is caused by expansion of a
CAG repeat in the huntingtin gene that is translated into an
elongated polyglutamine stretch within the N-terminal
domain of the huntingtin protein. The mutation is thought
to introduce a gain-of-toxic function in the mutant hun-
tingtin protein, and blocking this toxicity by antibody
binding could alleviate Huntington disease pathology.
Llama single domain antibodies (VHH) directed against
mutant huntingtin are interesting candidates as therapeutic
agents or research tools in Huntington disease because of
their small size, high thermostability, low cost of produc-
tion, possibility of intracellular expression, and potency of
blood-brain barrier passage. We have selected VHH from
llama phage display libraries that specifically target the
N-terminal domain of the huntingtin protein. Our VHH are
capable of binding wild-type and mutant human huntingtin
under native and denatured conditions and can be used in
Huntington disease studies as a novel antibody that is easy
to produce and manipulate.
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Introduction
Huntington disease (HD) is caused by expansion of a CAG
repeat within the first exon of the huntingtin gene (4p16.3)
[1]. This mutation results in an expanded polyglutamine
repeat (polyQ) at the N-terminus of the huntingtin protein
(htt), causing HD pathology through a toxic gain-of-func-
tion mechanism [2]. Antibody binding could reduce tox-
icity of the mutant htt protein. Messer et al. showed that a
single chain Fv antibody construct, selected against the first
17 N-terminal htt amino acids was capable of reducing HD
pathogenesis in various HD models [3, 4]. In our study we
make use of llama single domain antibody fragments called
VHH [5]. VHH contain four framework regions (FR1–4)
for structural integrity and three variable complement
determining regions (CDR1–3) that usually determine
epitope binding. VHH have distinctive advantages com-
pared with other antibody classes. VHH are thermostable,
only *16 kD in size and their single domain nature sim-
plifies selection and production [6, 7]. VHH have been
used for diseases such as oculopharyngeal muscular dys-
trophy (OPMD), which shares characteristics with HD.
OPMD is caused by expansion of a triplet repeat in the
PABPN1 gene that encodes for a polyalanine repeat at the
N-terminus of the polyA binding nuclear 1-protein
(PABN1). VHH binding to an a-helical domain of mutant
PABN1 prevented aggregation [8], and alleviated OPMD
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pathology in a drosophilia model [9]. In the current study,
we have selected VHH against the N-terminal domain of
htt from llama phage display libraries. We show that high
resolution melting curve analysis (HRMCA) [10] can
successfully identify identical clones prior to sequencing.
Our VHH can bind both endogenous and purified human
wild-type and mutant htt at an epitope located between
amino acids 49–148 and can co- immunoprecipitate htt
from human HD brain lysates.
Results
Selection of VHH against N-terminal huntingtin
The phage-VHH (P-VHH) display library originated from
llamas pre-immunized with an Escherichia coli produced
N-terminal htt protein fragment consisting of the first 548
amino acids with 46 polyQs. We performed four different
selections; each selection involved two rounds using either
a wild-type or mutant N-terminal htt fragment. Enrichment
of P-VHH after two rounds of selection was similar for
direct coating or pre-capturing of N-terminal htt in the first
round, with the optimal concentration being 5 lg N-ter-
minal htt (Online Resource 1a). P-VHH output numbers of
up to 3 9 104 were obtained. Screening ELISA revealed
that on average, 20 % of selected clones bound htt (Online
Resource 1b). Further screening by HRMCA (Online
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Fig. 1 VHH protein sequences.
iVHH 1–4 were selected from
an immunized llama phage
display library. nVHH was
selected from a non-immunized
llama phage display library.
Underscored amino acid
position differs from iVHH1.
Amino acid positions,
framework (FR, thin line) and
complementary determining
regions (CDR, thick line) are









































































Fig. 2 VHH specificity for N-terminal htt. Assays were performed on
a recombinant N-terminal htt fragment consisting of amino acids
15–378 with a polyQ length of 17 (htt a.a. 15–378 Q17). Positive
control: MAB5492. Negative control: No P-VHH or P-nVHH.
a ELISA on wells with (black bars), or without (white bars)
N-terminal htt. Bars represent mean ELISA signal from two
independent ELISA assays with standard deviation. Each assay was
performed in triplicate. ELISA absorption units are measured at
k = 490 nm. b Western blotting on N-terminal htt. Blots were
performed twice. kDa Molecular weight (kilodalton)
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htt specific VHH, (immune)VHH1-4. These differed by
one, two, or three amino acid substitutions in the CDR1
and CDR2, while the CDR3 was identical (Fig. 1). The
negative control VHH (n-VHH) was selected previously
from a naive llama phage display library [10].
Specificity of monoclonal iVHH for N-terminal
huntingtin
To investigate if the iVHH specifically bind htt, we per-
formed ELISA and western blot analysis on a normal and
mutant N-terminal htt fragment using P-iVHH [11]. ELISA
resulted in a positive signal for all P-iVHH (Fig. 2a, Online
Resource 2a). P-iVHH1, 2 and 3 showed an equally strong
ELISA signal, whereas P-iVHH4 gave a weaker signal. On
western blot, all P-iVHH showed a band that matched the
band obtained with the known htt antibody MAB5492
(Fig. 2b, Online Resource 2b). Western blotting results
were in agreement with ELISA results.
Epitope determination of iVHH on N-terminal
huntingtin
To determine the epitope of our iVHH, we performed
western blotting using three different N-terminal htt frag-
ments. Each fragment had a partially overlapping sequence
with the next fragment (Fig. 3). All fragments were recog-
nized by the 1H6 antibody [12] while 3702–1, that binds htt
at the N-terminal 13 amino acids (Online Resource 3a), only
recognized fragment I. All P-iVHH recognized all fragments
(Fig. 3, Online Resource 3b) indicating that their epitope is
located within the overlapping region of fragments I, II and
III that consists of amino acids 49–148. Finally, western
blotting with monomeric iVHH was performed. VHH were
produced with an average concentration of 1.1 lg/ll. Wes-
tern blotting using iVHH instead of P-iVHH recognized htt
fragments I, II, and III but with less back ground staining.
iVHH detection of endogenous huntingtin in human
HD brain lysates
Next, we analysed if our iVHH were capable of binding
endogenous human htt. We performed immunoprecipita-
tion experiments using monomeric iVHH and post-mortem
human HD brain lysates. Non-specific binding of htt to the
protA-beads without VHH (Fig. 4, –lane) was low.
Immunoprecipitation in the presence of iVHH resulted in
wild-type and mutant full-length htt band on western
blot, while the negative control VHH (nVHH) did not
show a full-length htt band (Fig. 4, Online Resource 4).
This shows that, in concordance with previous ELISA
and western blot results on N-terminal wild-type and
mutant htt fragments, our iVHH recognize both wild-type
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Fig. 3 VHH epitope determination. Western blots performed on no htt (-), htt a.a. 1–148 Q46 (I), htt a.a. 15–378 Q17 (II), and htt a.a. 49–415
(III). Primary antibody indicated below each blot. Blots were performed twice. kDa Molecular weight (kilodalton)





























Fig. 4 Immunoprecipitation of endogenous human htt with VHH.
Western blot analysis of VHH-htt immunoprecipitation complexes.
VHH used for htt immunoprecipitation indicated at top, Input, 10 lg
of brain lysate; –, No VHH. Arrow indicates full-length htt. kDa
Molecular weight (kilodalton). Blot was analysed with 3702-1 anti htt
antibody. Right bracket 39 enlargement of the iVHH3 immunopre-
cipitation result, showing wild-type (wt) and mutant (mut) huntingtin
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immunoprecipitation with iVHH4 was less efficient com-
pared with the other iVHH.
Discussion
To our knowledge, our study is the first in which VHH
have been selected against N-terminal htt protein fragments
from an immunized llama phage display library. Mono-
clonal antibodies are increasingly used as therapeutic
agents [13]. Proof of concept for using antibodies in HD
has been provided [3, 4]. Whilst this is promising, there are
high demands on any therapeutic or imaging antibody.
Because HD is a brain disorder, it is important to cross the
blood–brain barrier (BBB). Some VHH were able to cross
the BBB [14, 15]. Also, VHH diffusion throughout the
brain, and cellular uptake were demonstrated [15].
Although VHH selection from non-immune phage-VHH
libraries is possible [16], selection from immune llama
phage-VHH libraries is expected to yield more high-
affinity binders because of affinity maturation. However,
diversity will be less as affinity maturation selects for the
strongest binder. This is reflected in our results. Our iVHH
share a high degree of sequence homology. This indicates
that the binding epitope of our iVHH is very similar. Our
iVHH bind full-length and N-terminal htt in a native and
denatured conformation. Binding characteristics for
iVHH1-3 were comparable, whereas iVHH4 showed a
lower binding efficiency. This is probably due to a single
amino acid change in iVHH4 at position 55 in CDR2 where
the a-polar alanine was replaced with a polar serine.
Because both alanine and serine have side-chains of com-
parable sizes, it is conceivable that the lower binding
efficiency of iVHH4 is due to a shift from an a-polar to
polar amino acid. The epitope of all iVHH was mapped to
a region between amino acids 49 and 148 downstream of
the polyQ repeat, explaining why our iVHH bind both
wild-type and mutant htt. In this region, htt contains several
domains associated with HD pathogenesis. There is a
proline rich region involved in sequestration of other pro-
teins into htt aggregates [17]. Furthermore, proteolytic
cleavage between amino acids 104 and 114 was linked with
formation of intranuclear aggregates associated with
increased toxicity [12]. Binding of our iVHH in this region
could alleviate HD pathogenesis. However, it has to be
noted that our huntingtin-specific VHH could also block
neuroprotective properties of wild-type htt [18]. Additional
research is needed to assess the therapeutic properties of
our iVHH or their possible applications in HD research.
We have demonstrated the feasibility of using VHH for
immunoprecipitation, eliminating interference by IgG
bands in the subsequent western blot [19]. Furthermore,
since VHH have been used as imaging agent to stain
amyloid-b deposits in vivo in an Alzheimer disease mouse
model [20], our iVHH could be an interesting in vivo
imaging tool in HD models to visualize the htt protein.
Materials and methods
N-terminal htt fragments
A HTT reference sequence with 23 polyQs was used. For
PCR primers see Table 1. PCR products were ligated
directly into the pGEM-T easy vector (Promega, Madison,
WI, USA), digested with NcoI and SalI (Fermentas, St.
Leon-Rot, Germany), and ligated into a NcoI/XhoI (Fer-
mentas) pre-digested pIVEX 1.3 vector. Clones were
confirmed by sequence analysis. Htt protein fragments
were produced with the RTS-100 wheat germ CECF kit (5
PRIME, Gaitersburg, MD, USA) using the ProteoMaster
rapid translation system (Roche). To produce the N-ter-
minal htt 1–148 Q46 protein fragment, the HD1955 pCI
construct consisting of HTT nucleotides 1–1640 [21] was
cloned into a pRP261 vector using the NcoI/SalI restriction
sites, and re-cloned into the pET28 vector using the
BamHI/SalI restriction sites. The HD1955-pET28 construct
was digested with XhoI and self-religated, resulting in the
HD828-pET28 construct. Production and purification were
performed in BL21 codon? E.coli cells as described for
VHH. To prevent aggregation, dialysis was performed in
PBS ? 0.5 % Sarkosyl (Sigma–Aldrich).
VHH selection
Selections were performed as described [16]. The first
selection round involved a direct coating of NUNC maxi-
sorp plates (Thermo fisher Scientific, Rochester, NY, USA)
Table 1 Construction of N-terminal Htt fragments
N-terminal htt fragment Forward primer Reverse primer
a.a. 1–318 (Q17/Q43) TATGGCGACCCTGGAAA GTCGACGAGCAGCACGCCAAGA
a.a. 15–378 (Q17/Q43) CAAGTCCTTCCAGCAGCA GTCGACGGCTCCGGTCACAACA
a.a. 49–415 (no polyQ) GCCGCCTCCTCAGCTTC GTCGACGCCACCAGACTCCTCCTT
a.a. amino acid, Q17/Q43 polyQ stretch, Underscored SalI-site
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with 10, 5, or 2.5 lg of antigen, or a pre-capturing of 10 lg
antigen with 2, 1, or 0.5 lg of coated 1H6 antibody (Ab-
nova, Taipei, Taiwan). Phage-VHH (P-VHH) from the first
round were produced and purified as described [22] and
subjected to a second round of selection with 5, 2.5, or 1 lg
of directly-coated antigen. Purified P-VHH were stored at
-20 C in PBS containing 10 % glycerol. TG1 E. coli cells
were infected with phage-VHH from the second selection
round and plated on LB/Agar containing ampicillin. Ninety-
four randomly selected clones were tested as described [10]. As
secondary antibody for the screening ELISA, we used HRP
conjugated mouse anti M13 (GE Healthcare, Bucking-
hamshire, UK). VHH DNA was purified using the Nucle-
ospin Plasmid purification kit (Macherey–Nagel, Duren,
Germany) according to manufacturer’s instructions. DNA
was sequenced using primer M13REV (CAGGAAA
CAGCTATGAC). DNA to protein conversion: http://www.
bioinformatics.picr.man.ac.uk/research/software/tools/seque-
nceconverter.html. VHH sequence alignment: http://www.
ebi.ac.uk/Tools/msa/clustalW2.
VHH production
PCR was performed on M13 plasmid using primers iVHH-
FW (CGGAATTCCTTTAGTTGTTCCA), and iVHH-Rev
(CACATCATCATCACCATCACG), or nVHH-FW (CGCT
GGATTGTTATTACTCGC) and nVHH-Rev (CCTCA
GAACCCAAGACCA). PCR fragments were cloned into
pUR5850 [23] by SfiI and BstEII (Fermentas) digestion and
ligation. Clones were verified by sequence analysis and
transferred into Neb5 E. coli for production. VHH were
purified using the His6-tag with TALON metal affinity resin
(Clontech, Mountain View CA, USA) according to the
manufacturer’s instructions using 50 mM NaPO4, 0.3 M
NaCl, pH7 as wash buffer. Wash buffer with 150 mM
imidazole was used as elution buffer. Pooled eluates were
dialyzed against PBS using Cellu-Sep dialyze-tube MWCO
3500 (Interchim, MontluC¸on, France). VHH production was
checked on Coomassie staining (PageBlue, Thermo-Scien-
tific) and western blotting against the VSV-tag. VHH was
quantified with bicinchoninic assay (BCA, Thermo-Scien-
tific). VHH were stored in 5 % glycerol at -20 C.
ELISA
A 96-well NUNC maxisorp plate was coated with 0.1 lg/
well of antigen. Staining was performed using P-VHH
diluted 1:20, followed by HRP conjugated mouse anti M13
(Millipore Billerica, MA, USA). ELISA signal was visu-
alized with o-Phenylenediamine (OPD, Sigma–Aldrich).
Optical density at k = 490 nm was measured using a plate
reader (Biotek, Winooski, USA). The huntingtin-specific
antibody MAB5492 (Millipore) was used as positive
control.
Western blot
N-terminal htt fragments were run on a 10 % SDS-PAGE
gel and proteins were blotted onto nitrocellulose membrane
(#170-4159, Bio-Rad, Hercules, CA, USA). Blots were
blocked with 4 % non-fat milk (Nutricia, Schiphol, The
Netherlands) in TBST. Primary antibodies: 3702-1 (Epit-
omics, Burlinggame, CA, USA), MAB5492 (Millipore),
1H6 (Abnova, Taipei city, Taiwan), P-VHH or 20 ng/ll
VHH. Blots probed with VHH were subsequently incu-
bated with mouse anti VSV (Cell signalling). Secondary
antibodies: HRP conjugated goat anti-mouse, goat anti-
rabbit (Santa-Cruz), or mouse anti-M13 (Millipore). Bands
were detected with Amersham ECL (#RPN 2132, GE
healthcare) and Hyperfilm ECL (#28906837, GE
healthcare).
Immunoprecipitation assay
Human post-mortem brain tissue from the middle temporal
gyrus of a 67 year old female HD subject (CAG1: 15,
CAG2: 42) was obtained with the families full consent and
the ethical approval of the various institutional Ethics
Committees. Post-mortem delay was 9 h. VHH (15 lg)
was bound to 10 ll bed volume of protein A sepharose
beads (GE Healthcare), and incubated for 90 min with
100 lg of post-mortem human HD brain tissue lysate in
PBS. Western blot analysis of the VHH-htt complexes was
performed as described above, where SDS-PAGE was
performed according to [24].
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